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Side Effects May Vary: The Aftermath of the United States v.
Caronia Decision on Off-Label Drug Promotion
Christina Le
Christina.Le1@student.shu.edu
Introduction
On November 4, 2013,
health care giant Johnson & Johnson agreed to pay more than $2.2
billion to resolve criminal and
civil allegations of off-label marketing of three of its prescription
drugs: Risperdal, Invega, and
Natrecor.1 The civil settlement
with federal and several state governments totaled $1.72 billion.2
Further, criminal fines and forfeitures reached $485 million. This
settlement was the second largest
health care fraud settlement in
United States history.3 Less than
four months later, Endo Health
Solutions, Inc., and its subsidiary,
Endo
Pharmaceuticals,
Inc.,
agreed to pay $192.7 million to
resolve criminal and civil claims
for the off-label promotion of the
drug, Lidoderm.4 In a statement
about the settlement, Zane D. Memeger, United States Attorney for
the Eastern District of Pennsylvania, said, “pharmaceutical companies have a legal obligation to
promote their drugs for only FDA
-approved uses.”5 But what about
the companies’ constitutional
right to free speech? The United
States Court of Appeals for the
Second Circuit has been the only
circuit to hold that truthful, nonleading off-label promotion6 is
protected under the First Amendment in United States v. Caronia.7
Nevertheless, as evidenced by the

recent Johnson & Johnson and
Endo Health Solutions settlements, the free speech defense
introduced in Caronia does not
seem to be too promising for
pharmaceutical companies faced
with allegations of off-label promotion.
United States v. Caronia
When the United States
Court of Appeals for the Second
Circuit decided Caronia in December 2012, the case was hailed
as a “landmark” decision.8 It created a circuit split between the
Second Circuit and every other
federal circuit because the Second
Circuit was the only one to hold
that off-label promotion was protected free speech under the First
Amendment. Until this decision,
no court had held that off-label
promotion by pharmaceutical and
medical device manufacturers and
their representatives was protected
under the Free Speech Clause of
the First Amendment. This defense was not available when the
Food and Drug Administration
(“FDA”) prosecuted off-label promotion for violating the misbranding provisions of the Food, Drug
and Cosmetic Act (“FDCA”).
The defendant in Caronia
was convicted of conspiring to
introduce a misbranded drug,
Xyrem, into interstate commerce
in violation of the FDCA. On appeal, the defendant ultimately prevailed on the grounds that the offlabel promotion of the drug was

lawful and protected under the
First Amendment. In a 2-1 decision, the Second Circuit held that
prohibiting the lawful off-label
marketing of a drug unconstitutionally restricted free speech.
Further, it held that the misbranding provision does not prohibit off
-label promotion. The Second Circuit was the first Federal Court of
Appeals that interpreted the
FDCA’s misbranding provision to
not expressly prohibit off-label
promotion.
The Food and Drug Administration’s Views on Off-Label
Promotion
Before entering interstate
commerce, new drugs are subject
to approval from the FDA to be
marketed for specific uses.9 Once
the FDA approves a drug, physicians are free to prescribe it for
approved and unapproved, or “off
-label uses.”10 Under the FDCA,
introducing any adulterated or
misbranded drug into interstate
commerce is prohibited.11 A drug
is considered misbranded if its
label does not have adequate directions for use.12 “Adequate directions for use” is defined as directions under which laypersons
“may use the drug safely and for
the purposes for which it is intended.”13 “Off-label use” refers
to the use of a drug, or other product, in a way that is not indicated
on its FDA-approved label.14 This
term is applied when a drug is
used to treat a disease not indicat-
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ed on the FDA-approved label. In
addition, “off-label use” is also applied when prescribing the drug for
the indicated disease for a different
dosage or for a different patient population than indicated on the FDAapproved label.15
The FDA has acknowledged
that under certain circumstances, off
-label use may be appropriate, such
as when it is used as medicallynecessary standard of care.16 The
FDA has expressed reluctance to
interfere with the practice of medicine or create barriers to physicians
exercising their best judgment when
considering treatment options for
patients.17 The FDCA expressly
states that none of the provisions of
the Act “shall be construed to limit
or interfere with the authority of a
health care practitioner to prescribe
or administer any legally marketed
device to a patient for any condition
or disease within a legitimate health
-care-practitioner-patient relationship.”18
The prohibition against offlabel promotion is mainly directed
at pharmaceutical and medical device manufacturers and their
agents.19 A free speech violation
may exist when these manufacturers
and their agents are prohibited under
the Act, but physicians, and other
entities, such as medical journals,
are allowed to promote the off-label
use of drugs. The intent of physicians to promote a certain drug for
an off-label use is presumably driven by the best interests of the patient, whereas such promotion by a
pharmaceutical company and its employees is driven by profit, not safe-

ty. By promoting off-label uses,
dosage, and patient populations,
drug companies are able to expand its market to a broader
range of consumers and increase profits. Following the
2012 decision in Caronia, the
Federal Government argues that
off-label use is only evidence of
misbranding.20 The government’s argument is that promoting an off-label use is evidence
that the speaker is asserting an
intended use.21 Because it is off-

“Until this decision, no
court has held that off-label
promotion … was protected
under the Free Speech
Clause of the First Amendment.”
label, the labeling of the drug
does not bear adequate directions of this off-label use.22
Impact of Caronia: The Use of
the Free Speech Defense
Since the Caronia decision in December 2012, at least
one medical device manufacturer has asserted that off-label
marketing is constitutionallyprotected speech and is not a
violation of the FDCA. This
defense, however, has not been
universally successful. Some
courts adopted the Caronia decision,23 while others found it
was unpersuasive.24 The Caronia decision demonstrates an

expansion in commercial speech
rights in the context of pharmaceutical and medical device
marketing. Nevertheless, the
case law following the decision
suggests that the decision will
not significantly impact offlabel promotion.
Recently,
Medtronic, Inc. (“Medtronic”),
a medical technology company,
has faced numerous lawsuits
involving its InFuse Bone Graft/
LT-Cage Lumbar Tapered Fusion Device (“InFuse Device).
As a defense in these cases, the
company has utilized the Second Circuit’s holding that offlabel promotion does not violate
the FDCA. The FDA approved
the InFuse Device after its rigorous
premarket
approval
(“PMA”) process.25 The plaintiffs in the InFuse Device lawsuits against Medtronic contended that it was the off-label
promotion by Medtronic representatives to physicians that induced the physicians to perform
the spinal surgeries using offlabel methods.26 Specifically,
the plaintiffs alleged that the
representatives encouraged the
surgeons to implant only one
component in the three-part InFuse Device system and to use a
posterior approach during surgery, rather than the FDAapproved anterior approach.27
The plaintiffs claimed that the
off-label promotion of the device was executed without fully
disclosing all the adverse effects
and risks of the off-label uses.28
The plaintiffs further asserted
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that these two off-label approaches caused them to suffer from
resultant injuries.29 These injuries
ranged from severe bone growth,
pain, numbness, and difficulties
with certain motor function.30
Several United States District Courts31 and a Minnesota
state court have followed the Second Circuit’s decision in these
InFuse Device actions. These
courts have held that off-label
promotion is not unlawful under
the misbranding provision of the
FDCA and subsequently rejected
the off-label promotion and use
claims asserted by the plaintiffs.
The courts recognized that the
FDCA does not prohibit all promotion of off-label uses.32 The
United States District Courts and
the Minnesota state court identify
Buckman Company v. Plaintiffs’
Legal Committee as binding authority.33 The Supreme Court
held that physicians are able to
prescribe drugs and devices for
off-label uses.34 Moreover, the
Court recognized the importance
of not interfering with the practice of medicine and allowing
doctors to prescribe drugs and
devices for uses that have not
been approved by the FDA.35
In the above referenced
Medtronic cases, the plaintiffs
failed to establish a link between
off-label promotion and their respective injuries. The plaintiffs
could not state the specific statements made by Medtronic Inc., or
its agents, which induced the
physicians to use the device and
perform the surgery in an off-

label way. Since the plaintiffs
could not identify specific instances of off-label promotion to the
physicians, these courts adhered to
the Supreme Court’s presumption
in Buckman that physicians have
the discretion to use drugs and
medical devices in off-label ways
as long as they are an appropriate
course of treatment.36
Although the adoption of
the Caronia holding in the Fourth
and Fifth Circuit, as well as in a

“[The government] did not
believe that the Caronia
decision will impact the
FDA’s ability to enforce the
FDCA’s drug misbranding
provisions.”
Minnesota state court, would appear to be evidence of the persuasiveness of the holding in Caronia,
this is not the opinion held by all
courts. The Ninth Circuit decisions
in a number of InFuse Device cases37 and a decision in a Maryland
state38 court reveal that the Second
Circuit’s decision in Caronia is not
binding on jurisdictions outside
that circuit, and off-label promotion can still be illegal under the
provisions of the FDCA. These
courts rejected the holding under
Caronia and held that off-label
promotion violated the FDCA outright.
Based on the district and
state courts’ differing interpretations on whether the misbranding
provision of the Act prohibits offlabel promotion, it is unlikely that

the Caronia decision will affect
government litigation tactics or
enforcement efforts. Numerous
pharmaceutical
manufacturers
have pled guilty to charges of violating the FDCA by promoting off
-label uses and have settled with
the government.39 Following the
Johnson & Johnson settlement,
Attorney General Eric Holder
stated
that
the
settlement
“demonstrates the Justice department’s firm commitment to preventing and combating all forms
of health care fraud.”40 The government has adamantly prosecuted manufacturers and their representatives for off-label promotion
in the past.41 Between 2003 and
2007, the FDA issued 42 regulatory notices and demanded that
drug manufacturers cease circulating information about off-label
uses.42 During this period, the Department of Justice settled eleven
criminal and civil cases involving
off-label promotion.43
The government decided
not to bring the Second Circuit’s
decision to the Supreme Court for
further review. It did not believe
that the Caronia decision will impact the FDA’s ability to enforce
the FDCA’s drug misbranding
provisions.44 The likely reasons
for the government’s unwillingness to appeal the decision to the
Supreme Court are two-fold.
First, the Second Circuit’s decision in Caronia did not question
the validity of the misbranding
provisions of the FDCA or find a
conflict between these provisions
and the First Amendment. Sec-
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ondly, the Second Circuit did not
strike down the FDCA’s drug approval framework. Since the Caronia decision is only binding on
courts with the Second Circuit, the
government may not want to risk
a broadly applicable decision by
the Supreme Court—especially
since the Supreme Court’s decision in Sorrell seems to be protective of pharmaceutical speech.
Conclusion
Over a year has passed
since Caronia. What was once
hailed as a landmark decision, and
what appeared to be an expansion
in pharmaceutical speech, has had
little persuasive effect on the prosecution of off-label drug promotion by pharmaceutical companies. The government has remained steadfast in its commitment to prosecute for violations
under the misbranding provision
of the FDCA and in targeting
companies that promote drugs for
uses that have not been approved
by the FDA. Since Caronia, numerous pharmaceutical companies
have settled with the government
for allegations of misbranding
through off-label promotion, including three settlements in the
Second Circuit itself.45 Because
settlements with pharmaceutical
companies for off-label marketing
have been so successful, there is
little reason for the Department of
Justice to abandon its tactic of aggressive prosecution.46 Not only
will the government continue to
prosecute off-label promotion and

regard it as a per se violation of
the misbranding provision, but
pharmaceutical manufacturers are
also not optimistic that the Second
Circuit decision will be a useful
defense. Instead, pharmaceutical
companies appear to prefer to settle and plead guilty.
Furthermore, the government has an alternate avenue to
prosecute off-label marketing. It
could allege that off-label promotion violates the False Claims Act
(“FCA”). Under this alternative
claim, the government would allege that a pharmaceutical company promoted the sale and use of
drugs for uses that are not FDAapproved and not covered by the
federal health care programs; thus,
the promotion of off-label uses
would result in the submission of
false claims. Regardless of whether the government prosecutes offlabel promotion under the Food,
Drug and Cosmetic Act or under
the False Claims Act, it is evident
that a free speech defense is weak
at best. The “side effect,” or predicted results, of the Caronia decision have not been as desirable
as anticipated.
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Big Soda: The Key to Curbing Obesity in America?
Alice Anderson
Alice.Anderson@student.shu.edu
Introduction
It is no secret that Americans are struggling with their
health. The United States consistently ranks among the top ten
obese countries in the world.1 This
epidemic has become extremely
problematic for Americans: it is
not just expensive but it is killing
people. As the serious detrimental
consequences to America’s health
mount, state and local governments are attempting to fight the
problem head on by implementing
a number of policies that encourage Americans to curb their appetite and make smarter choices
when it comes to their health.
Sugar sweetened beverages, particularly soda, have become a
large target for these public health
initiatives.2 Famously introduced
by former New York City mayor
Michael Bloomberg, probably the
most restrictive health initiative
called for a 16-oz cap on soda at
restaurants, movie theatres, and
sports venues.3 More frequently,
state and local governments are
attempting to impose a one to two
penny-per-ounce tax on soda.4 As
a consequence soda manufacturers, often referred to as “Big Soda,” are painted in a negative
light.5 A clear comparison can be
made between this campaign and
the events surrounding the tobacco litigation of the 1990s.6 But,
with the complex interaction of
genes, lifestyle, culture, and socio-

economic status contributing to
obesity, are narrow restrictive
measures like a soda tax the key to
improving America’s health?
At a Glance: Obesity in America
The co-morbidity of obesity and chronic diseases makes the
current obesity epidemic a very
serious, not to mention expensive,
problem for the United States.7
Being overweight or obese drastically increases a person’s risk for
a number of serious and chronic
health problems, including coronary heart disease, Type 2 diabetes, certain types of cancer, and
stroke.8 According to the World
Health Organization, chronic diseases are the leading cause of
mortality in the world, making up
60% of all deaths.9 In addition to
the health risks, the estimated
medical cost of obesity in America is $147 billion per year.10 This
cost is primarily attributed to the
cost of treating the chronic diseases that are closely connected to
obesity, including the provision of
prescription drugs. As obesity
rates rise, so will the cost of dealing with the negative effects of
America’s weight gain.
The Soda Tax
Lawmakers can point their
fingers in many directions as to
whom to blame for the high obesity rates in the United States.11
Soda has been a relatively easy
scapegoat for officials to focus
upon. This is due not only to the

general popularity and prevalence
of these products, but also to the
high sugar content of sodas and
other sugar sweetened beverages
and their almost complete lack of
nutritional value. The typical
amount of sugar in any given soda
vastly surpasses the recommended
daily intake, a main reason why
sodas have been a large target of
public health campaigns.12 The
World Health Organization’s newest proposal recommends that the
average person should consume
no more than 25 grams of sugar a
day (which amounts to about 6
teaspoons).13 A 12 ounce can of
Coke has 39 grams of sugar (a little over 9 teaspoons of sugar).14
The soda tax is a relatively
new development in the national
effort to decrease obesity among
American adults and children.15
The tax is intended to reduce soda
consumption, thus reducing daily
sugar and caloric intake, which in
theory would reduce average
Body Mass Index (BMI).16 This
past year alone there were 26 bills
proposed across the United States
relating to taxes on sugarsweetened beverages, including
San Francisco, Chicago, California and Hawaii, though none of
these have been passed.17
These taxes have been met
with strong criticism. When research was released showing the
negative effects of smoking, a
similar situation emerged.18 In one
respect, it is hard not to compare
the obesity epidemic to tobacco.
The obesity epidemic, like the
harmful side effects of smoking,
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came as a shock to everyone.19 It
took a number of years to establish the taxes and policies we have
now for tobacco.20 Analogously,
many people today do not see how
soft drinks are harmful to them,
and, even if they do, they are not
willing to give them up. Consumers often do not look at the nutrition labels or if they do, they are
unable to decipher them. Consequently, many are not aware of the
actual nutritional content of soda.
In addition, many consumers who
are aware that soda contains high
levels of sugar or high fructose
corn syrup still continue to drink
soda regardless of its lack of nutritional content.21 This lack of
knowledge coupled with a lack of
concern makes it difficult to convince consumers that soda may be
harmful to their health, just as
with tobacco.22 Soda is also marketed in much the same way tobacco was, targeting children and
young adults who will grow up to
be the main consumer base of
these products.
The parallels between tobacco regulation and the new push
to start regulating the eating habits
of Americans are incredibly similar. This comparison signals that a
tax on soft drinks could be just as
effective as the tax on cigarettes
has been, especially on consumption by children and young
adults.23 Since tobacco taxes have
been in effect, studies have shown
that the tax has been effective in
reducing consumption, especially
in young adults.24 The theory is
that if the tax on tobacco has been

so successful, it should similarly
work to lower rates of consumption for soda, a less addictive
product.
The Benefits and Detriments of
Soda Taxes
Taxing soda seems to be a
decent remedy to a small part of a
larger problem. The only genuine
concern of taxes like the soda taxes is that they are, in theory, im-

posing lifestyle choices onto consumers by the government. Provided that the tax does not become
an arbitrary exercise of government power for the sole purpose
of raising money at the expense of
consumers or the businesses that
manufacture and produce soda, a
soda tax is a decently justifiable
policy to consider. These pennyper-ounce soda taxes will not be a
substantial economic burden to
any one group over another because they are relatively small.25 It
is unclear whether soda taxes will
do much to reduce actual consumption, but it will generate considerable revenue that could be
used to mitigate the already high
costs of healthcare or for programs that help educate the public
about healthy lifestyles.26 While

there is a strong link between soda
consumption and weight gain, it is
hardly the only culprit. Soda is not
the magic solution that will solve
the obesity epidemic in America,
but it is a worthy starting point.
Probably the largest concern these soda taxes raise is the
underlying use of governmental
power, and if public health is
something that a government has
the legitimate right to regulate.
Many Americans resent the government imposing their beliefs
about what a healthy lifestyle
looks like, as shown by the overwhelming backlash former mayor
Bloomberg received with his 16oz soda cap which was ruled unconstitutional (a ruling that is currently being appealed).27 The New
York Supreme Court Appellate
Division held in New York
Statewide Coal. of Hispanic
Chambers of Commerce v. New
York City Dep't of Health & Mental Hygiene that the Board of
Health did not have the power to
enact such a ban. The court looked
to the legislature as the source of
power to enact such a regulation.28
While many of the soda taxes are
proposed by state legislatures, not
many have been passed, indicating
that Americans seem to be resistant towards government regulation of health measures.29 These
concerns are valid; imposing such
a tax does incentivize behavior;
however, there is a big difference
between policies that restrict behavior among consumers and policies that incentivize behavior.
Opponents of the tax also
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argue that the tax will not only
restrict consumer freedom but will
negatively impact low-income
populations; however, these concerns are misguided. The opposition is concerned that the tax is
potentially harmful primarily to
low income households and also
to non-obese consumers. Opponents believe that soda taxes are
regressive, meaning they negatively impact lower income households. These groups believe that
the product’s increased cost as a
result of the tax will be passed
along to the consumers and not the
producers.30 Low-income households already spend a large portion of their monthly expenses on
food and beverage costs and typically buy soda because it is cheaper than the alternative choices
such as juice or milk.31 This
means that the soda tax is an unnecessary burden on a population
that spends a considerable portion
of their income on food and drink.
Minority populations also disproportionately purchase soda compared to other groups.32 Beyond
individuals with low-income and
minorities, there is also concern
that the tax is unfair to non-obese
or overweight consumers. By
charging everyone the same regardless of the consumer’s weight,
the tax does not discriminate
against overweight consumers and
non-overweight consumers. Thus,
the benefits for overweight and
obese customers would be at the
expense of non-overweight customers. Because the purpose of
soda taxes are to reduce obesity

and mitigate the related health
concerns associated with obesity,
opponents argue that asking nonobese people to finance this cost
with a soda tax is unfair.33
The concern of individual
freedom may be outweighed in
this case by the overall concern of
society’s health. Both the government and Americans themselves
are already feeling the impact of
the obesity epidemic: obesity costs
Americans a staggering $147 billion a year.34 This is not an arbitrary exercise of the government’s
power; it is an attempt to ensure
that Americans are healthy and not
unnecessarily wasting their money. Similar to tobacco, the nega-

“...the government and
Americans are feeling the
impact of the obesity epidemic: obesity costs
Americans a staggering
$147 billion a year.”
tive health impact on a large scale
necessarily gives the government
the ability to intervene, to an extent, a precedent which has been
set by tobacco itself.35 So long as
the taxes are reasonable and merely incentivize rather than restrict,
they are within the government’s
interest to impose and can hardly
be considered an undue restriction
on the freedom of consumers.
Concerns over the impact
on low income or non-obese persons are misguided. A penny-perounce tax is so small an increase
in price that it will hardly make an

impact (this, however, may raise
the question of why have the tax at
all).36 However, if a penny-perounce tax did indeed make sodas
expensive enough to become too
costly for lower-income consumers to afford, there are cheaper and
healthier alternatives available to
them. Economists believe that, in
raising the price of items like soda
that have no nutritional value,
consumers will turn to healthier
alternatives like milk which would
be less expensive than soda after
the tax increase.37 This makes the
tax an incentive rather than a restriction and illustrates the main
concept behind the idea of the soda taxes in general. Rather than
impose a ban which may be seen
as an over use of government
power (as discussed above), the
government can raise the price of
non-nutritional foods compared to
nutritional foods which might incentivize consumers to make
healthier choices. In the end, the
added cost onto sodas would pale
in comparison to the $147 billion
obesity already costs Americans
every year.38
Additionally, the revenue
generated by the soda tax can mitigate any unfair implications of
the tax by taking the money
gained by the tax and putting it
back into low-income communities. The Yale Rudd Center for
Food Policy and Obesity has developed a revenue calculator
which calculates the estimated
revenue a penny-per-ounce soda
tax would generate for each state
or major U.S. city.39 For instance,
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New York City alone would generate an estimated $345 million in
2014 from a soda tax. If these
funds were returned to lowincome areas, the revenue may
mitigate any disparities for lowincome households. For example,
the recent California bill imposing
a penny-per-ounce tax on soda
proposes to put all revenue raised
by the tax into the “Children’s
Health Promotion Fund,” a program that promotes children making healthy choices in diet and
exercise.40 The amount of money
these bills would raise is enough
to take notice. The revenue could
go a long way to fund future programs or even mitigate some of
the costs obesity has imposed on
the healthcare system. For instance, the money could help decrease the annual cost of
healthcare due to chronic diseases
caused by obesity, be put into research, or be used to fund programs to educate low-income
families on cost efficient ways to
have a healthy diet. The potential
benefit of such revenue is one of
the main reasons soda taxes are
popular among the state legislatures.41
Conclusion
America’s obesity epidemic will not go away anytime
soon. Soda taxes are but a small
part in a sea of regulations and
measures that the government has
proposed to help with the effects
of American obesity. Soda taxes
may not be the best solution, but

they do offer access to money that
can be used to fund more successful measures. Penny-per-ounce
soda taxes are not likely to be
very successful at curbing America’s soda addiction. The taxes are
a small increase in price that is
unlikely to stop most from buying
soda. If the government truly
wanted to discourage behavior,
they would have to drastically increase the price of soda, much
like it has done with the price of
cigarettes.42 As research continues
to show the negative effects of the
obesity rates in America, citizens
will be more likely to accept
measures such as a soda tax. For
now, however, the policy is met
with resentment and resistance by
the general public and is not likely to be successful in changing the
public’s attitude towards soda. If
the federal and state legislatures
can find better ways to incentivize
“healthy” behavior rather than
regulate unhealthy behavior, they
will be more successful in promoting
health
improvement
measures. A popular place to start
is with children. One new measure that the Obama administration
has recently unveiled is a plan to
ban all junk food advertisements
in schools, including soda.43 Ultimately, some regulation is necessary. Public health measures will
inherently include some sort of
imposed restriction on an individual’s behavior, but the numbers
show that American obesity has
become too big to ignore and it is
time for the government to get
serious about getting healthy.
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Emergency Medicaid:
Healthcare Reform and Undocumented Immigrants
Alexandra Pearsall
Alexandra.Pearsall @student.shu.edu

Introduction
A major issue surrounding
the Patient Protection and Affordable Care Act (PPACA), often referred to as “Obamacare,” concerns the nearly 12 million undocumented immigrants currently living in the United States and their
ineligibility to apply for federal
health care.1 Although federal law
does not allow undocumented immigrants to apply for health care
because of their illegal resident
status, undocumented immigrants
still have access to emergency
medical care under federal law.2
When it comes time to pay for the
emergency medical care given to
undocumented immigrants, providers often turn to Medicaid, specifically what is colloquially known as
“emergency Medicaid” because
Medicaid reimburses hospitals
when patients are unable to pay for
their emergency room bills. Funding for Medicaid is provided by
United States citizen taxpayers,
and it is estimated that 1.3 billion
dollars of taxpayer money goes
towards “emergency Medicaid.”3
Because of the heated debate over
illegal immigration in the United
States and the heavy burden on
taxpayers to support these illegal
immigrants, the issue of extending
federal health care to undocumented immigrants is highly controversial. This article considers why it
would be beneficial to American

citizens to allow illegal immigrants parts of the world and, in order to
to have the right to apply for health ensure public health from the varicare.
ous strains of illnesses and diseases, undocumented immigrants
The Difference Between Medi- must be able to access medical sercaid and “Emergency Medicaid” vices. When an illegal immigrant
is struck with these “emergency”
Medicaid provides health conditions, they have the federal
coverage to “more than 50 million right to obtain medical services
children, families, pregnant wom- from hospitals, which in turn proen, the elderly, and people with tects American citizens from these
disabilities.”4 It is available in eve- very conditions.10 Diane Rowland,
ry state and it pays for a “full set of executive vice president for the
services for children, including pre- nonpartisan Kaiser Family Founventive
care,
immunizations, dation writes that “from the perscreening and treatment of health spective of our health-care system,
conditions, doctor and hospital vis- when people show up and they’re
its, and vision and dental care.”5 sick, the health-care system is obAdditionally, these services are of- ligated to take care of them.”11 It
ten provided at no cost to families.6 seems just and fair to provide
However, undocumented immi- these types of services to nongrants are not eligible for federally citizens, whether they have enfunded public health insurance pro- tered illegally or not. However, a
grams such as Medicaid.7 There- much debated issue comes from
fore, when undocumented immi- how medical providers are affordgrants are not eligible under these ing to provide this medical care to
circumstances to apply for Medi- undocumented immigrants.
caid, they must resort to
After medical assistance,
“emergency Medicaid” in order to hospitals may try to bill the undocseek professional medical treat- umented immigrant patient first.12
ment.
However, if the patient cannot pay
The
existence
of for any reason, the hospital will
“emergency Medicaid” does bene- turn to “emergency Medicaid” to
fit society as a whole, in that its recoup their costs.13 In 2011, the
purpose is to prevent the spread of federal government paid out 1.3
communicable diseases and to en- billion dollars under “emergency
sure general health.8 In this con- Medicaid”.14 Additionally, states
text, “emergency” means “sudden- paid “hundreds of millions of dolonset conditions that threaten life lars” to repay hospitals for these
or could cause serious impair- services.15 Sandhya Somashekhar
ment.”9 This is highly beneficial to wrote in the Washington Post, that
every American citizen because a “large percentage” of the finanimmigrants travel from all different cial burden imposed on hospitals
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is labor and delivery costs because
the majority of patients that use
“emergency Medicaid” are pregnant women.16 These costs likely
will only increase as immigrants
continue to enter the United States
illegally. Therefore, there is a
strong need for health care reformation. Allowing undocumented
immigrants to apply for federal
health care would alleviate the burden on taxpayers who fund
“emergency Medicaid.”

to bodily functions; or (iii)
Serious dysfunction of any
bodily organ or part…19
This provision protects the safety
of American citizens because if
an undocumented immigrant is
permitted to acquire medical care
to prevent such symptoms that
could be indicative of communicable diseases, then undocumented immigrants will not pose as a
threat to American health safety.

Why Illegal Immigrants Cannot
Apply For Federal Health Care
The legal authorization to
limit federal health care services to
illegal immigrants comes from The
Code of Federal Regulations of the
United States. 42 C.F.R. § 440.255
limits services available to illegal
immigrants to certain circumstances
and conditions.17 § 440.255(c) addresses aliens who are not lawfully
admitted for permanent residency
in the United States.18 The pertinent
part states that an illegal alien must
receive the services necessary to
treat this condition:
The alien has, after sudden on
set, a medical condition
(including emergency labor and
delivery) manifesting itself by
acute symptoms of sufficient
severity
(including
severe
pain) such that the absence of
immediate medical attention
could reasonably be expected
to result in: (i) Placing the
patient's health in serious jeopardy; (ii) Serious impairment

Therefore, though undocumented
immigrants are not allowed access to federal Medicaid, the fact
that they have access to
“emergency Medicaid” shows
that undocumented immigrants
still can obtain the vital medical
care that they require.
Additionally, the Supreme
Court in the 1976 case Mathews
v. Diaz ruled that limits are
placed on the ability of illegal immigrants to obtain medical benefits and services.20 At the time,
“in order to qualify for Medicaid
benefits, a noncitizen had to be
lawfully admitted to the United
States and continuously reside
therein for the five years preceding application for benefits.”21 In
Diaz, the Court found that Congress is not required to provide

every benefit it provides to citizens to all aliens, nor must it extend identical benefits to every
distinct class of alien.22 Patrick J.
Glen, in his article titled “Health
Care and the Illegal Immigrant”
reasons that “The Constitution
does not require identical treatment for every individual in the
United States, citizen or alien, or
identical treatment across different
classes of aliens.”23 The Diaz ruling remains good law and can be
cited as precedent that health care
does not need to be extended to
illegal immigrants.
Finally, in 1986, Congress
enacted the Emergency Medical
Treatment and Active Labor Act
(EMTALA), which was meant to
provide patients with access to
emergency medical care and “to
prevent hospitals from ‘dumping’
unstable patients that could not
afford to pay for their care.”24
Even though EMTALA refers specifically to hospitals with an
Emergency Department, the federal government has applied the law
requirements to “all facilities that
participate in the Medicare program and offer emergency services.”25 Therefore, over time the
concept that undocumented immigrants cannot apply for federally
funded public health insurance
programs has been solidified,
while simultaneously the ability
for undocumented immigrants to
obtain emergency care has been
legally recognized in hospitals
around the country.26

VOLUME VII, ISSUE 2

PAGE 14

“Emergency Medicaid”
PPACA And “Emergency Medicaid”
Somashekhar writes that
the issue of taxpayers subsidizing
health care for undocumented immigrants will likely expand under
Obamacare.27 Somashekhar defines undocumented immigrant
“emergency Medicaid” issues as:
“reimbursement offered to hospitals to provide emergency and
maternity care to people who,
based on their income and other
factors, would be eligible for regular Medicaid if only they weren’t
a) in the country illegally, or b) in
the country legally but not lawful
long enough to join Medicaid
(five years).”28 Additionally, Phil
Galewitz, in his article “How Undocumented Immigrants Sometimes Receive Medicaid Treatment” writes:
A little-known part of the state
-federal health insurance program for the poor pays about
$2 billion a year for emergency treatment for a group of
patients who, according to
hospitals, mostly comprise
illegal immigrants. Most of it
goes to reimburse hospitals for
Delivering babies for women
who show up in their emergency rooms, according to
interviews with hospital officials and studies.29
Galewitz writes that this funding
accounts for less than one percent
of the cost of Medicaid and the
percentage “underscores the political and practical challenges of
refusing to cover an entire class of

people.”30
Galewitz uses Florida as
an illustration of the impact of
illegal immigrants in the health
system.31 Galewitz cites Joanna
Aquilina, the chief financial officer of Bethesda Healthcare System in Boynton Beach, Florida,
who says: “We can’t turn them
away.”32 Aquilina sees many illegal immigrants because of the
hospital’s proximity to farms that
harvest sugarcane and other seasonal crops.33 Galewitz writes:
Nearly one-third of Bethesda
Hospital East’s 2,900 births
each year are paid for by
Emergency Medicaid, the
category that covers mainly
illegal immigrants. The category includes a small proportion of homeless people and
legal immigrants who’ve
been in the country less than
five years. Hospitals can’t ask
patients whether they’re illegal immigrants, but instead
determine that after checking
whether they have Social Security numbers, birth certificates or other documents.34
Additionally, “one study of Medicaid spending from 2001 to 2004
in North Carolina estimated that
99 percent of emergency Medicaid recipients were illegal immigrants.”35 This demonstrates a real
issue exists with the distribution
of emergency Medicaid in the
United States for illegal immigrants, which places a high financial burden on American taxpayers.

Why The United States Should
Extend Health Care to Illegal
Immigrants
Health care for illegal immigrants has become a hotly debated topic, as the United States
has been unable to curtail the influx of illegal immigrants from
several countries around the
world. PPACA is part of the U.S.
Department of Health & Human
Services (HHS). Observing the
aims of the current health reform,
the website for HHS makes it
clear that only Americans are covered. HHS states: “The mission of
the Department of Health and Human Services is to help provide
the building blocks that Americans need to live healthy, successful lives.”36 Further, the website
writes: “The Department of
Health and Human Services
(HHS) is the United States government’s principal agency for
protecting the health of all Americans and providing essential human services, especially for those
who are least able to help themselves.”37 This issue, however,
goes well beyond an isolated argument for allowing undocumented immigrants the right to health
care.
Some pundits argue that
access to health care is a basic human right, analogous to education
and employment.38 Michael J.
McKeefery in his article, “A Call
to Move Forward: Pushing Past
the Unworkable Standard That
Governs Undocumented Immigrants’ Access to Health Care Un-
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der Medicaid” writes that one perspective is to realize that undocumented immigrants are human beings and “it is their moral right to
have access to services that are essential to sustaining life.”39 Further, some undocumented immigrants are children who have had
no choice but to follow their parents.40 Therefore, it would seem
unfair to deny these basic human
rights to innocent children. Finally,
scholars contend that undocumented immigrants are found to pay
more in taxes than they collect in
benefits; many undocumented immigrants stay in the United States
for a “substantial period of time”
and thus contribute much to their
communities by paying taxes.41
Therefore, undocumented immigrants serve as a valuable asset to
the economy.
The other side of the argument is that undocumented immigrants should not be entitled to apply for Medicare because the cost
considerations justify excluding
undocumented immigrants from
coverage.42 McKeefery writes that
“tax-supported services, like federal health care plans, cannot sustain
the increase in demand that would
result if undocumented immigrants
were included in public health care
programs.”43 Other substantial arguments are that immigrants who
reside illegally in the United States
should not be allowed to receive
the benefits of health care coverage
because undocumented immigrants
do not usually pay taxes to support
federal
programs.44
Finally,
McKeefery argues that by denying

coverage to undocumented immigrants, it would “likely create a disincentive for individuals to enter
the United States illegally.”45 Thus,
there is a strong argument for continuing to bar undocumented immigrants ability to apply for Medicare
and to further restrict undocumented
immigrants
access
to
“emergency Medicare.”

“[O]ne study of Medicaid
spending from 2001 to 2004
in North Carolina estimated that 99 percent of emergency Medicaid recipients
were illegal immigrants.”
Considering both sides of
the debate, it is hard to deny what
the United Nations, of which the
United States is a charter member,
considers to be fundamental and
basic human rights. Article 25 of
The Universal Declaration of Human Rights protects the right to
adequate medical care:
Everyone has the right to a
standard of living adequate for
the health and well-being of
himself and of his family, including food, clothing, housing
and medical care and necessary
social services, and the right to
security in the event of unemployment, sickness, disability,
widowhood, old age or other
lack of livelihood in circumstances beyond his control.46
The purpose of the United Nations
is to “achieve its goals and coordinate efforts for a safer world for

this and future generations.” In
addition, the UN has provided an
Article that specifically addresses
the need to provide all humans
with adequate medical care. Since
the Untied States is a charter member of the UN, how does the United States have any right to deny
this emergency medical care to
undocumented immigrants on
American soil?47
Conclusion
There are certainly many
powerful and compelling arguments on both sides of the debate.
However, from a humanitarian
perspective, it seems that the only
fair and reasonable solution to this
issue is to extend the ability to apply for Medicare to undocumented
immigrants because it would eliminate the issue of American taxpayers needing to pay for immigrant medical care and also allow
undocumented immigrants to take
the necessary steps in order to cover themselves when future medical
ailments arise, thus protecting national health and economy. Therefore, eligibility for all federal
health care programs ought to extend to undocumented immigrants.
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President Obama’s Notable Advance toward Battling Health
Care Fraud
Anna Vaysberg
Anna.Vaysberg@student.shu.edu
Health care fraud is a
white-collar crime that involves
the filing of dishonest health care
claims in order to make a profit.
This fraud occurs in many ways
and the list encompasses individuals obtaining subsidized or fullycovered prescription pills that are
medically unnecessary and then
selling them on the black market
for a profit; billing by practitioners for care that they never rendered; filing duplicate claims for
the same service rendered as well
as countless others.1 In fact, the
ways to defraud are continuously
increasing while detection has become increasingly more difficult.2
Health care fraud costs the country an estimated $80 billion dollars a year and that figure has
been growing exponentially. Due
to this fact, health care fraud has
been attracting political attention
and was most recently placed to
the legislative forefront by President Obama. The graph shows
the increase of health care fraud
prosecutions in the last 20 years.
As is readily apparent, Obama’s
administration has been the most
efficient and proactive with regards to combating health care
fraud. President Obama’s efforts
to ramp up the fraud and abuse
investigations resulted in $4.1 billion recovered in 2011.3 The increasing number of prosecutions
shows that the steps the President
has taken including expanding the

Health Care Fraud Prevention and
Enforcement
Action
Team
(HEAT), increasing the punishment for those accused, and lessening the standard required for
prosecution of health care fraud
cases, which have all proven to be
effective in tackling fraud within
our health care system.
President Obama has specifically addressed the issue of
fraud in relation to Medicare in-

“[Health care fraud]
violations can now occur
whether or not the
individual has actual
knowledge or specific intent
to commit a violation.”
surance. Medicare and Medicaid
programs comprise the largest single purchaser of health care in the
world, and account for over twenty percent of all U.S. federal government spending.4 Thus, much
of the fraud that occurs is targeted
at Medicaid and Medicare insurance providers. HEAT is at the
forefront of investigating and
prosecuting for such crimes. Since
the creation of HEAT in 2009, the
Medicare Fraud Strike Force, (a
branch of HEAT) has expanded
from 2 to 9 locations and more
than 320 defendants were charged
with allegedly billing more than
one billion dollars in false claims.
The locations now span the entire
country with offices in the following states: Louisiana, New York,
Illinois, Texas, Michigan, California and Florida.5

The Patient Protection and
Affordable Care Act of 2010
(PPACA) has revised preceding
provisions dealing with health
care fraud. One goal of the revision was to disincentivize this
type of fraudulent behavior by
increasing the level of punishment. Specifically, there has been
a two-level increase in the offense
level for any defendant convicted
of a federal health care offense
relating to a government health
care program which involves a
loss of up to $1 million; a threelevel increase in the offense level
for any defendant convicted of a
federal health care offense relating to a government health care
program which involves a loss of
up to $7 million and a four-level
increase in the offense level for
any defendant convicted of a federal health care offense relating to
a government health care program
which involves a loss of up to $20
million.6 So what would have
previously been punished on a
scale of a misdemeanor has the
possibility of being punished as a
felony. Increasing the risk associated with committing such a
crime is thought to be proportionate with a reduction of such
crimes.
President Obama, through
the PPACA, has also lessened the
standard of criminal culpability
required for the prosecution of
health care fraud cases.7 Specifically, there has been a diminished
requirement in terms of the mens
rea—the subjective intent—
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required for prosecution of health
care fraud cases. Prior to the passage of the PPACA, a conviction for
health care fraud under 18 U.S.C. §
1347, required the government to
prove that the defendant: (1) knowingly and willfully executed, or attempted to execute, a scheme or artifice; to (2) defraud a health care
benefit program or to obtain by false
or fraudulent pretenses any money
or property under the custody or
control of a health care benefit program; (3) in connection with the delivery of or payment for health care
benefits, items, or services.8 The
passage of PPACA has relaxed the
scienter–guilty knowledge— requirement by inserting subsection
(b), which states: “With respect to
violations of this section, a person
need not have actual knowledge of
this section or specific intent to
commit a violation of this section.”9
This wording encompasses a broader range of violations by not requiring intent to commit. Simply put,
prior to PPACA the government had
to prove that an individual knowingly and willfully executed, or attempted to execute, a fraudulent
scheme or artifice. PPACA has lowered the bar for the prosecution by
relaxing that standard. Violations
can now occur whether or not the
individual has actual knowledge or
specific intent to commit a violation. If fraud occurred, the person
will be held accountable.
As can be seen from the
aforementioned examples, President
Obama has stepped right into the
forefront of America’s battle with
health care fraud. Over the past few

years, we have seen a 75% increase in the number of individuals whom we have charged with
criminal health care fraud due to
actions by HEAT and the prosecution of more than 1,400 defendants who collectively falsely
billed the Medicare program
more than $4.8 billion.10
In conclusion, the number
of agencies dealing with health
care fraud has increased and there
has been more severe punishment
for those convicted of health care
fraud. In addition, the standard of
culpability needed for the prosecution of health care fraud cases
has been reduced. These changes
have been successful initiatives
in battling health care fraud.
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Data Mining & Electronic Health Records: HITECH Act’s
“Meaningful Use” and “Secondary Use” of Health Data
Donna Hanrahan
Donna.Hanrahan@student.shu.edu

Healthcare providers are
establishing electronic health record
(EHR) systems at an astonishing
rate, due in part to the Health Information Technology for Economic
and Clinical Health (HITECH) Act.
The HITECH Act was created as a
part of the American Recovery and
Reinvestment Act of 2009.1 The
$27 billion dollar piece of legislation offers eligible providers incentives for expanding the use of
healthcare information technology
(HIT).2 This includes promoting the
“meaningful use” of EHRs. The
“meaningful use” standard was designed to use HIT to improve quality of care and health outcomes for
patients, as well as to lower costs
by eliminating repeat medical tests
and reducing preventable medical
errors that pervade the health-care
system today. This legislation has
been extremely effective in persuading healthcare providers to use
EHRs. In fact, the incentives outlined in the HITECH Act are estimated to increase EHR adoption
rates to 90% of all physicians by
2019.3 Despite healthcare technology’s vast potential to improve patient health in the medical arena, a
host of complex legal, technical,
and ethical issues surrounding the
use of HIT as incentivized in the
HITECH Act still exist, specifically
privacy, confidentiality, autonomy,
and the preservation of the physician-patient relationship. By reevaluating, clarifying, and enforcing

HIPAA guidelines as they pertain
to secondary use of EHRs, researchers can access large valuable
data sets without compromising
patients’ rights to privacy and autonomy. However, EHRs cannot be
considered a cure-all for patient
health. We must acknowledge the
potential detrimental effect it may
have on the physician-patient relationship. It is important to provide

“[T]he secondary use of
health data for research has
great potential to improve
health outcomes, reduce
medical errors, predict
health trends, and demonstrate the comparative value of drugs and other treatments.”
patients with the right to dictate
which information they choose to
share and allow them to opt out of
the platform to protect patient autonomy while optimizing the research potential of electronic health
data.
The
HITECH
“Meaningful

Act

and
Use”

The HITECH Act offers
hospitals and eligible healthcare
professionals incentives for expanding the use of healthcare information technology, including the
“meaningful use” of EHRs.4 Incentive payments are made available
through the Medicaid and Medicare programs. The Centers for

Medicare & Medicaid Services
(CMS) judges whether a healthcare
provider has satisfied the meaningful use core objectives through the
use certified health technologies.
The Department of Health
and Human Services (HHS) defines
“meaningful use” as using certified
EHR technology to: (1) improve
quality, safety, efficiency, and reduce health disparities; (2) engage
patients and families; improve care
coordination, and population and
public health; and (3) maintain privacy and security of patient health
information.5 This “meaningful
use” framework incentivizes improvements to clinical care and
quality by encouraging healthcare
professionals to take advantage of
instantaneous and patient-specific
information.
There are three stages of
“meaningful use.” The first stage is
the use of HIT for basic data collection, including demographic and
medication history. The second
stage is the use of EHR data to improve clinical processes including
patient controlled data, clinical decision support, health information
exchange, and quality measurement
and research. The third stage is the
use of EHR data to improve health
outcomes, quality, safety, efficiency, and population health at the national level.6 Hospitals and providers eligible for the EHR Incentive
Program do not need to attest to
meaningful use in their first year of
participation. Rather, healthcare
entities must simply implement an
EHR to receive an incentive pay-
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ment from their State.
The HITECH incentive payments are quite substantial. To receive payments, eligible professionals and hospitals must meet at least
5 of the “meaningful use” criteria
defined, consisting of 15 core data
points and 10 menu options.7 The
criteria require the entry of patient
demographic and insurance information, e-prescribing, and the use
of drug interaction software to ensure patient safety. 8 Eligible professionals and hospitals that meet the
criteria can be rewarded up to
$44,000 in Medicare and $63,750 in
Medicaid payments over 5 years.
After 2015, all physicians who fail
to meaningfully use EHRs will be
subject to reductions in Medicare
and Medicaid reimbursement.9
Health Information Exchanges

state level, governments are creating statewide health information
networks (HINs). At the national
level, the Office of the National
Coordinator (ONC), which oversees deployment of the HITECH
Act, is executing plans to create an
NHIN. Provider organizations participating in NHIN include Kaiser
Permanente, the Cleveland Clinic,
and the Veterans Administration.

These networks can lead to
the development of data repositories filled with rich sets of health
data for millions of individuals.
Such data repositories can provide
researchers with information necessary to improve quality of care
and make significant discoveries in
medicine that they may not otherwise have access to. Despite their
great potential, progress in developing HIEs and repositories has
been gradual. Many hospitals and
clinics are hesitant to implement
the systems because they do not
have the finances or infrastructure
necessary to do so.12 Moreover,
there are also significant concerns
over patient privacy and autonomy.

The HITECH Act is a step
towards the eventual goal of a national, interoperable, private, and
secure electronic system to allow
information to be shared among all
the sites where patients receive
care.10 While still in its infancy,
Health Information Exchanges
(HIEs) are being established at the
community, state, and national level
to facilitate the electronic exchange
between systems. The State Health
Information Exchange Cooperative
Agreement and the Nationwide
Health
Information
Network
(NHIN) received $600 million in Secondary Use of Health Data
federal funding to create a platform
for health information exchange
Until recently, collecting
across the United States.11 At the data for “secondary use” was an

arduous task. “Secondary use” in
healthcare is defined as the use of
information collected from health
records, electronic or manual, outside of direct patient care delivery.
This includes data collection for the
purpose of “research, quality and
safety measurement, public health,
payment, provider certification or
accreditation, marketing, and other
business applications.” 13 Such use
of healthcare data in biomedical
research has the potential to drastically improve the quality and affordability of healthcare services in
the United States. EHRs contain
structured information about patients, which is extremely valuable
in research because now information can be retrieved in a much
quicker and more efficient fashion
than more traditional methods of
record keeping. Researchers can
develop algorithms to search
through EHRs, including free-text
clinician notes, to find data valuable
to a specific study.14
By providing researchers
with rich ready-made large data
sets, the secondary use of health
data for research has great potential
to improve health outcomes, reduce
medical errors, predict health
trends, and demonstrate the comparative value of drugs and other
treatments.15 Other benefits include
the increased ability to analyze the
efficacy of treatment options and
identify evidence-based best practices. Furthermore, predictive modeling techniques may be applied to
electronic health data to identify
medical conditions before the onset
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of symptoms and promote earlier
interventions. While experimental
studies, such as randomized controlled clinical trials, are likely to
continue to be the gold standard of
clinical research compared to observational studies, they are more
expensive and time consuming. As
such, electronic health data serves
as a rich resource for the conduction of valuable observational studies which can be performed quickly
and inexpensively.
Nevertheless, the unprecedented surge in the amount of
healthcare data, as well as the relative ease with which that data can
be aggregated and exchanged between providers and researchers,
raises ethical questions about its use
in research, particularly concerning
patient privacy and autonomy. The
Health Insurance Portability and
Accountability Act (HIPAA) requires protected health information
(PHI) to be de-identified or authorized by the patient for release in
order to be used in research. However, de-identified data would
omit significant clinical, demographic, and time-related data that
would render the data sets much
less useful for many research purposes. While de-identified data
leads to incomplete data sets, it
seems like a small price to pay for
protecting the privacy of patients,
especially those with stigmatized
conditions.
Accordingly, researchers are
forced to walk a fine line between
ensuring
patient
privacy
and maximizing the descriptive
power of their data sets. Before the

research value of secondary use
can be fully realized, ethical considerations surrounding the mining of electronic health data must
be explored, namely infringements on an individual's privacy,
confidentiality, and autonomy. It
is necessary to establish a national framework of policies for the
secondary use electronic health
data to allow stakeholders to harness valuable information to improve
the
United
States’
healthcare systems while maintaining patient autonomy and privacy protections.16
Data

Quality

Concerns

The mass amount of recent electronic health data makes
it possible to assess the overall
burden of disease and evaluate
the impact of interventions on a
national scale. Despite its promise, research through electronic
health
data
mining
and
“secondary use” is not without
flaws. Data quality concerns are
inherent in data that is being used
for any purpose other than what it
was originally intended, especially considering the fragmented nature of the healthcare industry and
the numerous platforms on which
data is being collected.17 First,
there are hundreds of different
EHR systems, each with a distinct
representation of data that makes
it difficult to aggregate.18 Second,
even within the same EHR system, information incompleteness,
inaccuracy, and inconsistency are
common challenges.19 Different

healthcare professionals tend to
use the same system differently.20
Third, clinicians tend to prefer using free text compared to structured data entry because it is more
easily adapted to their individual
practice styles and work flows,
although it may make it more difficult to compile and analyze.21
Fourth, incomplete and duplicate
records threaten the quality of research using data mined from
EHRs.
Some critics may argue
that EHRs make it more possible
for clinicians to falsify charts and
reports, which would lead to both
data quality and trust issues with
patients. However, the falsification
of records would not only violate
the moral imperative against lying,
but also infringe on the fiduciary
relationship between the physician
and patient. Furthermore, there are
methods to protect against such
acts, including audits, fraud charges, and reclamation of funds under
the False Claims Act and the Deficit Reduction Act.22 These
measures are valid disincentives to
data falsification when it comes to
patient records.
Lastly, while the incentives
and mandates of HITECH and
“meaningful use” have led to an
enormous amount of data being
stored and generated by the U.S.
healthcare system, there is an extreme lack of interoperability. The
electronic data exists in different
formats on hundreds of different
systems. Aggregating this sizeable
amount of data for research purposes will prove difficult, if not
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impossible, without a national regulatory framework to reduce intersystem variation and improve data
quality. The federal government
must determine national data standards or guidelines and clinicians to
decrease data variation between
systems.23 By implementing legislation to address these issues, the
federal government can alleviate
many ethical concerns while allowing the United States healthcare
system to benefit from more effective and larger scale use of secondary
data.
HIPAA and Privacy Concerns
With improved access to
data comes increased risk of wrongful disclosure of patient health information. Human error, hacking,
IT glitches, and theft or loss of
hardware that contains such information are just a few possible risks.
HITECH challenges certain notions
of privacy and security found in
HIPAA yet enhances others.
HIPAA prohibits the disclosure of
protected health information (PHI)
without the consent of the patient
except for the purposes of treatment, payment, or healthcare operations. Under HIPAA, “business associates” of covered entities with
access to PHI are not directly regulated.24 Rather, they are obliged to
comply with HIPAA pursuant to
mandatory written agreements
within the covered entities for
which they work. The HITECH
Act, on the other hand, provides for
regulation of business associates
and stipulates that HIPAA’s priva-

cy and security rules directly apply to them.
When it comes to security
breaches involving PHI, HITECH
mandates public notification
when unsecure, unencrypted PHI
is disclosed or used for an unauthorized purpose, similar to many
state and federal financial data
breach laws. The HITECH Act
also requires that patients be notified of both internal and external
breach of their data security. If a

“Data quality concerns are
inherent in data that is being used for any purpose
other than what it was originally intended…”
breach affects over 500 patients,
HHS must also be notified and
the name of the breaching institution will be posted on the HHS
web site. There are also certain
circumstances where local media
will need to be notified to inform
the public of breaches than effect
many people within a given area.25
While HITECH is a federal law, HHS and state officials are
granted with the authority to enforce the law. Subtitle D of the
HITECH Act addresses the privacy and security concerns of EHRs
by strengthening both the civil
and criminal enforcement of the
HIPAA rules.26 Section 13410(d)
of the HITECH Act revised the
Social Security Act by establishing significant penalties for violations of security policy of the
HITECH Act.27 If an institution

or individual is unaware of a violation despite due diligence, the
minimum penalty is $100 per violation, with a cap of $25,000 for
violations of an identical requirement within the same year.28 If the
security violation is due to “willful
neglect,” the minimum penalty is
$10,000 per violation, with a cap
of $250,000.29 The maximum penalty is $50,000 per violation, with
a cap of $1.5 million.30 These are
clear examples of the HITECH’s
acts attempts to deter data breaches and mitigate security concerns.
The healthcare industry
continues to tread carefully when
it comes to pursuing “meaningful
use” of HIT while protecting patient privacy under HIPAA regulations. Some argue, however, that
the current HIPAA regulations do
not accommodate the powerful
research opportunities that may
become possible as HIT and HIEs
become more commonplace. The
public health benefits of secondary
use merit careful consideration of
how such data can be optimized
while protecting patient autonomy.
Autonomy, Informed Consent,
and Syndromic Surveillance
Several ethical considerations must be addressed before a
national framework is implemented to address issues of autonomy
and informed consent. Patient autonomy is threatened when an individual’s PHI is shared without
that person’s knowledge or consent. When data mining electronic
health data, it is unlikely that pa-
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tients are told that their data is being accessed. It is even less likely
that they are contacted for their
consent.
This is concerning, as champions of patient autonomy argue
informed consent is necessary for
the secondary use of health data.
Patients often believe they have a
right to know who is viewing their
medical information, why it is being accessed, and how it is being
used. Additionally, those who
champion patient autonomy believe
that patients have a right to take an
active part in decisions about the
access, content, and ownership of
EHR data. It would appear to be a
violation of autonomy to aggregate
and generate new information about
a patient’s health without their
knowledge or permission. Patients
provide information to healthcare
professionals in confidence with the
specific goal of advancing their
own personal health outcomes. If
the principle of autonomy is intrinsically linked to advancing an individual’s own personal health outcomes, then any form of secondary
use (by definition as the use of PHI
outside of direct patient care delivery) appears to be a violation of the
principle of “respect for persons.”
A critical question here is whether
or not you can turn a patient into a
research subject without their
knowledge or consent.
To overcome these issues of
autonomy, patients should be able
to access their EMRs with relative
ease. Moreover, patients should
maintain the right to have a degree
of control over the records’ content.

While it seems unreasonable to
allow patients to modify or delete
any of the content entered by
healthcare professionals per se, it
seems judicious to allow autonomous patients to review, annotate,
or challenge their own electronic
medical record. Furthermore, federal regulations must be reassessed to determine what is considered valid informed consent
for research using electronic
health data specifically. Some
HIEs are attempting to develop
new consent processes to overcome HIPAA compliance issues.
Some are calling for a blanket
“opt-in” or “opt-out” policy,
while others suggest the independent ability to exclude certain
types of sensitive data in one’s
own health record.31 Ideally, to
maintain the highest level of patient autonomy, the patient would
have full say as to what specific
information may be shared and
with whom it may be shared.
Certain public health situations, though, necessitate the use
of electronic health data without
informed consent. This is particularly true during public health
emergencies. Syndromic surveillance systems seek to use existing
health data in real time to provide
immediate analysis for early detection of disease outbreaks, and
to monitor disease trends.32 In the
interest of population health, the
HITECH framework allows for
syndromic surveillance to notify
public health officials of reportable conditions.33
It is also necessary to note

the point of “electronic exceptionalism.” There is a longstanding
history of manual disease surveillance. However, it seems more
ethically unsettling when this process is done with high technology
tools that can quickly aggregate
and share data in unprecedented
ways. While critics may look at
syndromic surveillance through
EHR data as exceptional because
of its electronic nature, its use may
not be so different than traditional
methods after all. There has been
mandatory reporting of certain
conditions to public health officials at the local and national level
for decades before EHRs existed,
including the reporting of drugresistant tuberculosis, certain cancers, and HIV. EHRs will make
reporting of these conditions and
others deemed necessary to protect
public health easier, and may actually do a better job at protected
patient health data by encrypting
and preventing unauthorized access through password protection.
Meaningful for Whom?
It is clear that the
“meaningful use” of EHRs is on
the rise, but is important to question for whom is it meaningful,
and how meaningful is it? Let us
consider one of the primary goals
of “meaningful use,” which is to
provide patients with electronic
resources to increase participation
in their own care. Patients are provided with an electronic copy of
their health information within
three business days if requested,
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Continued...
including diagnostic test results,
medication lists, allergies, discharge summaries, and procedures.34 Accordingly, providers often offer patients access to their
online personal health record
(PHR). PHRs are largely secure as
they are encrypted and passwordprotected. However, it is important
to note that patients need more than
just Internet access and a very basic
understanding of health information
to fully benefit from PHRs.35 Not
only must patients be able to read
and interpret lab results; they must
be willing and capable to act on the
information he or she receives.
This point has been largely neglected in discussions surrounding the
HITECH Act. For those without
access to the Internet, those with
very limited health literacy, and
those unable to act on that information for financial or other reasons, EHRs have limited to no direct benefit. It is important to
acknowledge these limitations and
ethical concerns under the HITECH
Act. In response, one must consider
community outreach and education
programs that focus on Internet and
health literacy, rather than merely
advertising new electronic and personal health record capabilities.36
Many fear that patients will misunderstand or misinterpret information if they read it without a
medical professional to interpret it.
It is possible that the HITECH Act
granted healthcare providers a new
ethical obligation to work with patients to ensure they understand
these tools and how to use them.
Furthermore,
healthcare

professionals run the risk of relying solely on PHRs to communicate important health information
to their patients. This stands to
cause great harm to the doctorpatient relationship. Electronic
tools must not replace the face-toface communication between the
healthcare provider and patient
that is essential to maintaining
trust and achieving improved
health
outcomes.

“[F]ederal regulations must
be reassessed to determine
what is considered valid informed consent for research using electronic
health data…”
It has been well established that the government has the
police power authority to regulate
for the safety and welfare for the
population. However, it is important to consider from a bioethical perspective where the line
ends between public health surveillance and an intrusion on
one’s own individual liberty and
autonomy. On the other hand, it
could be argued that it would be a
“tragedy of the commons” if individuals independently acted according to each one's self-interest
and refused to be surveilled. To
take a communitarian perspective,
aggregation of public health data
is an essential resource to public
health officials and necessary for
the welfare and beneficence of
the population as a whole.

Beneficence of Electronic Data
in Medical Research
Despite the ethical concerns addressed above, the use of
electronic health data is critical to
ensuring patient health, improving
our healthcare system, and making
new scientific discoveries in this
technological age. Critics may
question whether EHRs are truly
meaningful or whether it is an
“excessive bureaucratic requirement to spend public dollars on
doctors’ computer systems.”37
The answer to this question can be
discussed through the principle of
justice. One can argue that it is
ethical to expend public funds for
EHR systems that provides for the
greater good and benefits for the
public as a whole. Data that is well
-structured and easily retrievable
benefit clinicians, patients, and the
greater population. These benefits
include safer prescribing, prevention of medication errors, epidemiological tracking to protect population health, and public medical
error reporting. Furthermore, there
is a clear demand to switch from
outdated, burdensome, and inefficient clinical charting traditions to
electronic format.
EHR adoption aims to reduce cost, which is a primary goal
of health reform in the United
States.38 The increase in information available to clinicians can
help prevent redundant or unnecessary tests and imaging. Furthermore, EHRs can provide point-ofcare clinical decision support
(CDS) as doctors prescribe tests,
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medications, and imaging requests,
which can also help reduce costs.
EHRs can also enable users to
measure desired outcomes and report this data more quickly and easily, saving both time and money.
With regard to the costs associated
with EHRs, studies demonstrate
strong returns on financial investment that may be achieved following EHR implementation.39 Other
financial benefits include increased
revenues due to improved care coordination, averted costs of paperwork, chart pulls, and billing errors,
and fee-for-service savings including the rate of new procedures and
charge capture.40
In addition, the secondary
use of health record information is
anticipated to become one of the
healthcare industry’s greatest assets
and the key to greater quality and
cost savings over the next five
years.41 A recent report by the
McKinsey Global Institute, estimates the potential annual value to
the healthcare industry at over 300
billion dollars.42 These savings in
cost benefit both the patient and
provider.
There are also several patient-centered benefits that result
from the “meaningful use” EHR
data. Perhaps one of the most promising results of EHR data mining is
the use of predictive modeling techniques to identify medical conditions and promote interventions before the onset of symptoms. Furthermore, retrospective analysis of
the health data mined from EHRs
could expedite scientific discovery
in medicine by providing valuable

information for research. In addition, physicians’ access to data
and analysis could demonstrate
the efficacy of different treatment
options across large populations,
which could help treat and prevent chronic conditions. Lastly,
such data can be used to identify
evidence-based best practices,
identify potential patients for clinical trials, and monitor patient
compliance and drug safety.
These measures show beneficence towards the patient by
providing better more individualized care.

“It is possible to reconcile
the use of electronic health
data for research while
maintaining respect for patient’s autonomy.”
Conclusion
EHRs can facilitate the
efficient delivery of healthcare in
a cost-effective, safe, and patientcentered way. The safety and privacy of patients and potential research participants is of utmost
concern and can be maintained
while capitalizing on technological advances to improve the United States healthcare system. It is
possible to reconcile the use of
electronic health data for research
while maintaining respect for patient’s autonomy. Accomplishing
this will require collaboration
among ethicists, researchers, clinicians, informatics specialists,
and policy makers.43 By reevalu-

ating, clarifying, and enforcing
HIPAA guidelines as they pertain
specifically to secondary use, the
federal government could point the
healthcare field in a direction that
both protects of patients’ privacy
and autonomy while empowering
researchers with valuable data
sets. Permitting the establishment
HIEs and data repositories of EHR
data for research purposes has
great potential for identifying evidence-based best practices, monitoring patient compliance and drug
safety, and showing the efficacy of
different treatment options across
large populations. However, we
must provide patients with the
right to dictate which information
they choose to share and allow
them to opt out of the platform to
protect patient autonomy while
optimizing the research potential
of electronic health data. Moreover, EHRs cannot be considered a
cure-all for patient health and we
must acknowledge the effect it
may have on the physician-patient
relationship.
The HITECH Act’s initiatives take us a step closer to President Obama’s stated goal of “an
EHR for every American by
2014.”44 The integration of HIT
into our healthcare system is more
than just a technological upgrade;
it represents a fundamental change
in our approach to healthcare practice. EHRs will continue to evolve
as a critical component in the medical field, and can be ethically integrated to deliver the highest
quality healthcare to Americans in
the 21st century.
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